A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) (NCT06285643)
A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease
🩺 Plain-English Summary (8th-Grade Level)
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic — Phoenix, Arizona
Age range: 45 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (46 Sites)
Showing the first 25 of 46 sites.
- Mayo Clinic — Phoenix, Arizona
- UCI Alpha Clinic (Neurology) — Irvine, California
- Loma Linda University (Neurology) — Loma Linda, California
- Loma Linda University (Surgical) — Loma Linda, California
- University of California San Francisco (Neurology) — San Francisco, California
- University of San Francisco (Surgical) — San Francisco, California
- CenExel Rocky Mountain Clinical Research (Neurology) — Englewood, Colorado
- Georgetown University (Neurology) — Washington D.C., District of Columbia
- Parkinson's Disease and Movement Disorders Center of Boca Raton (Neurology) — Boca Raton, Florida
- University of Florida — Gainesville, Florida
- University of Miami — Miami, Florida
- Orlando Health Neuroscience Institute — Orlando, Florida
- Parkinson's Disease Treatment Center of Southwest Florida (Neurology) — Port Charlotte, Florida
- Emory University (Surgical) — Atlanta, Georgia
- Rush University Medical Center (Neurology) — Chicago, Illinois
- University of Kansas Medical Center (Neurology) — Kansas City, Kansas
- Massachusetts General Hospital (Neurology) — Boston, Massachusetts
- Massachusetts General Hospital (Surgical) — Boston, Massachusetts
- Michigan State University (Neurology) — East Lansing, Michigan
- Quest Research Institute (Neurology) — Farmington Hills, Michigan
- Cleveland Clinic Lou Ruvo (Neurology) — Las Vegas, Nevada
- Columbia University — New York, New York
- University of North Carolina (Neurology) — Chapel Hill, North Carolina
- Duke Neurosurgery (Surgical) — Durham, North Carolina
- Duke University (Neurology) — Durham, North Carolina
📞 Contact the Study Coordinator
Phone: (919) 388-1040
Email: askfirst@askbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Parkinson Disease
- Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation — Tucson, Arizona
- Parkinson's Disease Progression Study — Aurora, Colorado
- To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications — Birmingham, Alabama
- Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower) — Seattle, Washington
- Automated Imaging Differentiation of Parkinsonism — Birmingham, Alabama
- Study in Parkinson Disease of Exercise — Birmingham, Alabama
Explore by condition: All Parkinson Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.